View Author
ifn -β bxpc -3 cells expression effect cancer combination protein treatment activation activity p 27 expression phosphorylation *** control growth stat -3 increase signi pathway pancreatic vitale experiment aneurysm type i ifns inhibition pancreatic cancer cells cycle signi ficantly analysis autophagy factor survival troglitazone sinus eif 4e phosphorylation concentration tecnology inc ppar -γ antitumor activity valsalva kinase caraglia biotechnology transfection agent beclin 4 ° c apoptosi receptor pancreatic cancer error bars incubation advance §§§ speci method interferon methods ”. 169–184 ficant mechanism complex ficantly stat -3 activation signal speci fic antibodies antibody intensity 0.001 noncoronary sinus cancer cells phase growth inhibition agonist valsalva aneurysm probe result tumor deviation assay
2 Most Recent Publications
|
The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells
(Article)
Vitale, G. Zappavigna, S. Piccoletti, R. Koetsveld, P.M. van Cavagnini, F. Budillon, A.M. Abbruzzese, A. Hofland, L.J. Caraglia, M. Marra, M. Dicitore, A. Meschini, S. Condello, M. Arancia, G. Castiglioni, S. Maroni, P. Bendinelli, P. |
2012-01-01
|
|
Giant aneurysm of Valsalva's sinus: Diagnosis and preoperative planning using 64-slice computed tomography
(Article)
Palumbo, A.A. Maffei, E. Cademartiri, F. Martini, C. Reverberi, C. Agostinelli, A. Nicolini, F. Budillon, A.M. Borrello, B. Beghi, C. Gherli, T. |
2010-07-01
|
